Abstract
ObjectiveCongenital heart diseases are observed in 5 to 8 of every 1000 live births. The presence of a valuable biomarker during the surgical periods may aid the clinician in a more accurate prognosis during treatment.MethodsFor this reason, surfactant protein B plasma levels may help to evaluate patients with cardiac problems diminishing the alveolocapillary membrane stability. In this study, plasma levels of this biomarker were measured in the preoperative and postoperative periods. This study was conducted to detect the differences between pulmonary hypertensive and normotensive patients. The differences before and after cardiopulmonary bypass were examined.ResultsThe differences in cardiopulmonary bypass time, cross-clamp time , inotropic support dose, and duration of intensive care of patients with and without pulmonary hypertensive were found to be statistically significant (P<0.05). The results revealed that this pathophysiological state was related to other variables that were studied. We believe that the differences in preoperative and postoperative SPB levels could be attributed to alveolocapillary membrane damage and alveolar surfactant dysfunction. We found that this pathophysiological condition was significantly associated with postoperative parameters.ConclusionThe findings of the current study showed that surfactant protein B was present in the blood of patients with a congenital heart disease during the preoperative period. Long by-pass times may exert damage to the alveolocapillary membrane in patients with pulmonary hypertension and preoperative heart failure, and it is recommended to keep the option of surfactant therapy in mind during the postoperative course at the intensive care unit before preparing the patients for extubation.
Highlights
Cardiac surgery has been a rapidly developing scientific area that has experienced many innovations in the second half of the last century
Long by-pass times may exert damage to the alveolocapillary membrane in patients with pulmonary hypertension and preoperative heart failure, and it is recommended to keep the option of surfactant therapy in mind during the postoperative course at the intensive care unit before preparing the patients for extubation
Surfactant protein B (SPB) is a protein that is normally undetectable in peripheral circulation, but it enters into the bloodstream when the structure of the alveolocapillary membrane is disrupted for any reason
Summary
Cardiac surgery has been a rapidly developing scientific area that has experienced many innovations in the second half of the last century. The rapid advances in surgery have created a need for markers to guide intensive care follow-up[1]. The discovery of a biomarker that will guide the postoperative intensive care follow-up, aid in anticipating complications, shape treatment, and facilitate decision-making for the duration of intensive care follow-up has great benefits. Surfactant protein B (SPB) can be used for the aforementioned purposes; since it is not present in the peripheral blood of healthy individuals, but rather enters into the peripheral bloodstream as a result of a pressure imbalance in the pulmonary alveolocapillary membrane due to heart failure[1]. SPB is used as a biological marker to determine the degree of pulmonary dysfunction in adult patients with heart failure and the detection of the response to medical treatment. The research on the use of SPB in congenital cardiac surgery has not been sufficient yet[2]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
